MedTrace Logo

Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women

NCT00545077 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 380

Last updated 2023-03-31

Study results available
· View outcomes & findings →

Summary

Locally advanced or metastatic breast cancer in postmenopausal women with negative Human Epidermal Growth Factor Receptor 2 (HER2), who are candidates for hormone treatment and who have not received previous chemotherapy or hormonotherapy for the metastatic disease.

Conditions

Interventions

DRUG

Letrozole

DRUG

Bevacizumab

DRUG

Fulvestrant

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • GBG Forschungs GmbH

    collaborator OTHER

  • Spanish Breast Cancer Research Group

    lead OTHER

Principal Investigators

  • Study Director · GBG Forschungs GmbH

  • Study Director · Hospital San Carlos, Madrid

  • Study Director · Hospital Provincial de Córdoba

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-06
Primary Completion
2013-12-31
Completion
2014-07-24

Countries

  • Germany
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00545077 on ClinicalTrials.gov